Organogenesis (ORGO:NASDAQ) Annual Reports & Investor Relations Material

Overview

Regenerative medicine company Organogenesis Holdings Inc. is making strides in the advanced wound care, surgical and sports medicine markets in the United States with its innovative product offerings. The company's advanced wound care products, such as Affinity and Novachor, preserve cells growth factors/cytokines, and ECM proteins in native tissue. Other products include Apligraf, Dermagraft, NuShield, PuraPly, FortiShield, FiberOS and OCMP. Its pipeline products include PuraPly AM, PuraPly XT, PuraPly MZ, PuraForce and TransCyte, catering to a range of wound types. Organogenesis serves various healthcare facilities through its networks of sales representatives and independent agencies. The company, founded in 1985, is headquartered in Canton, Massachusetts.

Frequently Asked Questions

What is Organogenesis's ticker?

Organogenesis's ticker is ORGO

What exchange is Organogenesis traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Organogenesis's headquarters?

They are based in Canton, Massachusetts

How many employees does Organogenesis have?

There are 501-1000 employees working at Organogenesis

What is Organogenesis's website?

It is organogenesis.com

What type of sector is Organogenesis?

Organogenesis is in the Healthcare sector

What type of industry is Organogenesis?

Organogenesis is in the Drug Manufacturers - Other industry

Who are Organogenesis's peers and competitors?

The following five companies are Organogenesis's industry peers:

- MediaValet

- Diurnal Group plc

- Neoleukin Therapeutics

- Evolus

- Elanco Animal Health